Aktienanalyse zu HeartBeam, Inc. (BEAT)BEATHeartBeam, Inc.

HeartBeam, Inc. is a cardiac technology company. The Company focuses on developing and commercializing higher resolution ambulatory Electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease both inside and outside a healthcare facility setting. It is engaged in the development of higher resolution ECG solutions is achieved through the development of the Company’s proprietary and patented electrocardiography technology platform. It is developing three-dimensional (3D) representations of cardiac electrical activity by displaying the spatial locations of ECG waveforms. It is developing its own product, the HeartBeam System. The HeartBeam System comprises a credit card sized 12-lead output electrocardiogram device, a patient application, a physician portal, and powerful cloud-based algorithms. The core technology consists of a series of patented inventions that allow it to capture the heart’s electrical activity from three distinct directions. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Heartbeam Inc is not a good buy right now due to its current price of $0.47, which is significantly below the analyst price targets of $2 and $5. The stock has a low RSI of 33.905, indicating it is oversold, but the ongoing losses, with a net income of -$4.7 million in Q1 2026 and a year-to-date change of -80.79%, raise concerns about its financial health. The main risk is the company's high negative cash flow, with a cash and cash equivalents total of only $2 million, down from $4.4 million, indicating liquidity issues.

7 analysts cover BEAT: 7 rate it Buy, 0 Hold and 0 Sell. The average price target is 5.83.